ArticleIrish journal of medical science2025
The clinical effects of miR-26a, miR-16, let-7, miR-128a and miR-223 in acromegaly.
Article in Irish journal of medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundMicroRNAs (miRNAs) have been shown to function either as oncogenes or tumor suppressors, depending on the cellular context. This study aimed to explore the potential involvement of specific miRNAs in pituitary tumorigenesis and to assess their association with clinical features in patients diagnosed with acromegaly.
methodsThe study comprised 39 acromegaly patients and 39 healthy controls who were matched for age and gender. Real-time PCR was used to determine the miR-26a, let-7, miR-16, miR-223 and miR-128a levels in peripheral blood. The patients' treatment methods, radiographic characteristics of the adenoma, and demographic characteristics were assessed.
resultsWhile patients with acromegaly and controls had similiar miR-26a, miR-16 and miR-128a levels, acromegalics had non-significantly lower let-7 levels [0.68 (0.45-1.05) vs.1.04 (0.53-1.94); p = 0.053] and significantly higher miR-223 levels [1.90 (0.75-3.23) vs. 0.86 (0.52-1.41); p = 0.021] compared to controls. No significant associations were observed between miRNA expression levels and radiological features of the adenoma, including tumor size, optic chiasm compression, and invasion of the cavernous sinus. Moreover, miR-26a expression is demonstrated to be increased in patients who required medical treatment after surgery (n: 26, 66.6%) [1.22 (0.93-1.73) vs. 0.74 (0.61-1.07); p = 0.004].
conclusionThe decreased expression of the tumor-suppressive let-7 and increased levels of the oncogenic miR-223 suggest a potential role in pituitary tumorigenesis in acromegaly. Although these miRNAs were not linked to tumor characteristics, elevated miR-26a expression may serve as a prognostic marker for long-term treatment needs in acromegaly patients.
Indexed as
Identifiers
40788444What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.